Germicide testing on surrogate devices supported by Olympus in comments on draft guidance.
This article was originally published in The Gray Sheet
Executive Summary
LIQUID CHEMICAL GERMICIDE TESTING WITH DEVICE SURROGATES SUPPORTED BY OLYMPUS in Aug. 20 comments to FDA. Commenting on FDA's December 1996 draft guidance for germicide 510(k)s, endoscope manufacturer Olympus America, Inc. says that "surrogates would enhance the standardization of simulated use testing by minimizing potential procedural variations and increasing the troubleshooting capability of the investigators."
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.